fianlimab

Regeneron Pharmaceuticals faces investor claims of inflating stock prices by overstating the potential of a skin cancer treatment's clinical trial, which later failed to meet approval benchmarks. Investors allege the company minimized risks of trial delays while describing the drug combination as a 'potential blockbuster,' leading to significant stock price declines after the trial's failure was disclosed.